Effects of a standardized extract of Withania somnifera (Ashwagandha) on depression and anxiety symptoms in persons with schizophrenia participating in a randomized, placebo-controlled clinical trial
Gannon JM, Brar J, Rai A, Chengappa KNR
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists · 26 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2019-05-01 · Ann Clin Psychiatry · vol. 31 · número 2 · págs. 123–129
- Editorial
- National Institutes of Health
- Citado
- 52 citas · más que el 98% de estudios similares · 7.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Schizophrenia research and treatment · Banking Sector Performance and Management
- Palabras clave
- Withania somnifera, Anxiety, Placebo, Depression (economics), Schizophrenia (object-oriented programming), Psychiatry, Medicine, Randomized controlled trial, Adverse effect, Internal medicine, Psychology, Alternative medicine
- MeSH
- humans, withania, antipsychotic agents, plant extracts, treatment outcome, double-blind method, depression, anxiety, schizophrenia, brief psychiatric rating scale, adult, aged, middle aged, female, male
4 autores
- Jessica M. Gannon🇺🇸UPMC Health System; University of Pittsburgh Medical Center
- J.S. Brar
- Rai A
- K N Roy Chengappa
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Extracts of Withania somnifera (WSE), or Ashwagandha, has traditionally been used as an adaptogen in Ayurvedic medicine, and evidence suggests that it may have efficacy in the treatment of psychiatric disorders, including schizophrenia. This secondary analysis reviewed change in depression and anxiety symptoms in a study using WSE as an adjunctive treatment in patients with schizophrenia experiencing an exacerbation of positive symptoms.
Methods
We enrolled patients with schizophrenia in a 12-week, randomized, placebo-controlled, double-blind study. Active treatment was with 1,000 mg of standardized WSE. This analysis reviewed outcomes for 66 patients with depression and anxiety symptoms by examining the singleitem depression and anxiety-depression cluster subscores extracted from the Positive and Negative Syndrome Scale.
Results
Medium effect sizes of 0.683 (95% confidence interval [CI], 0.16 to 1.21) and 0.686 (95% CI, 0.16 to 1.21) favoring WSE over placebo were observed for depression single-item and anxiety-depression cluster scores, respectively. Adverse events were mild and transient.
Conclusions
Our findings suggest that WSE may hold promise in the treatment of depression and anxiety symptoms in schizophrenia. While the mechanism of its clinical efficacy requires more exploration, the data suggest.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.